Metoject Pen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This limits the proliferation of rapidly dividing immune cells and also promotes the release of anti‑inflammatory adenosine, thereby reducing inflammation in autoimmune conditions.

The dose of Metoject Pen is individualized by the prescribing healthcare professional based on the specific disease, severity, patient weight, renal and hepatic function, and response to therapy. Only a qualified prescriber should set the dosing schedule and any adjustments.

Methotrexate is classified as teratogenic and is contraindicated during pregnancy because it can cause fetal malformations and miscarriage. It is also generally not recommended while breastfeeding, as it may be excreted in breast milk and affect the infant. Women of child‑bearing potential should use effective contraception.

To place an order, submit an enquiry on the Metoject Pen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

Metoject Pen delivers methotrexate, a cornerstone DMARD with a well‑established efficacy and safety profile. Compared with biologic agents, methotrexate is less expensive and administered subcutaneously, offering convenient self‑injection. However, biologics may be chosen when patients do not respond adequately to methotrexate or when a faster onset of action is required.

Metoject Pen should be stored at 2‑8 °C (refrigerated). Keep the pen in its original packaging, protect it from light, and avoid freezing or shaking the device. Do not use the product if it has been exposed to temperatures outside the recommended range.

Metoject Pen is a pre‑filled, single‑use injector designed for subcutaneous injection. The patient or caregiver removes the safety cap, selects the prescribed dose by turning the dose selector, and injects the medication into the subcutaneous tissue of the abdomen, thigh or upper arm as instructed by a healthcare professional.

The most serious risks include severe liver toxicity, bone marrow suppression leading to anemia or infections, pulmonary fibrosis, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver enzymes, blood counts and respiratory symptoms to detect these complications early.

Metoject Pen should not be used by individuals who are pregnant, planning to become pregnant, or breastfeeding. It is also contraindicated in patients with severe renal or hepatic impairment, known hypersensitivity to methotrexate, or active infections that could be worsened by immunosuppression. A healthcare professional must evaluate suitability before prescribing.